Hope vs hype: Doctors split over ‘game-changing’ experimental Alzheimer’s drug

Some experts say the benefits of lecanemab are “extremely small”, but others including Associate Professor Michael Woodward dispute this

“Impressive”. “Remarkable”. “Game-changing”.

There was no shortage of praise for the experimental dementia drug lecanemab following the release of phase III trial results late last year.